Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This appears to be an unusual combination of four antimicrobial agents that is not documented as a standard therapeutic regimen in clinical practice. The combination includes ampicillin (a penicillin), an aminoglycoside (likely gentamicin, tobramycin, kanamycin, or amikacin), cephalothin (a first-generation cephalosporin), and ceftriaxone (a third-generation cephalosporin). While ampicillin plus aminoglycosides and ampicillin plus ceftriaxone are well-documented combinations for treating various bacterial infections, particularly for enterococcal infections, the four-drug combination is not described in standard treatment guidelines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ampicillin + aminoglycoside + cephalothin + ceftriaxone.